Hysterectomy with TUbectomy (HYSTUB) study
Completed
- Conditions
- premature ovarian Faillure10029903
- Registration Number
- NL-OMON40051
- Lead Sponsor
- TweeSteden ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 110
Inclusion Criteria
Otherwise healthy women undergoing hysterectomy for benign indications (eg. bleeding disorder, fibroids, adenomyosis) without a family history of ovarian / tubal / breast cancer, will be asked to participate.
Exclusion Criteria
Family history of cancer, history of any form of cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>concentration AMH, FSH and oestradiol pre- and six months postoperatively.<br /><br>Does a salpingectomy during hysterectomy for benign indications change hormonal<br /><br>status significantly, indicating a shift towards menopausal status?</p><br>
- Secondary Outcome Measures
Name Time Method <p>What is the incidence of premalignancies in Fallopian tubes from women not at<br /><br>hereditary high risk to develop serous carcinomas? Is there a difference in<br /><br>quality of life (QoL) between the two groups?</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of hysterectomy with tubal ligation in managing premature ovarian failure?
How does hysterectomy with tubal ligation compare to standard hormonal therapies for premature ovarian failure in long-term outcomes?
Are there specific biomarkers that predict successful patient selection for hysterectomy with tubal ligation in premature ovarian failure cases?
What are the potential adverse events associated with hysterectomy in patients with premature ovarian failure and how can they be managed?
What are the current trends in surgical interventions for premature ovarian failure, and how does the HYSTUB approach fit within this landscape?